| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV | Chief Financial Officer | Common Shares | 0 | $0 | $1.63 | 13 Nov 2025 | Direct |
| ANTARES PHARMA, INC. | Executive Vice President & CFO | Common Stock | 0 | $5.60 | 24 May 2022 | Direct | |
| ANTARES PHARMA, INC. | Executive Vice President & CFO | Stock Option (right to buy) | 0 | 24 May 2022 | Direct | ||
| LAVA Therapeutics NV | Chief Financial Officer | Share Options (Right to Buy) | 0 | 13 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LVTX | LAVA Therapeutics NV | 13 Nov 2025 | 2 | $0 | 4 | Chief Financial Officer | 17 Nov 2025, 16:30 |
| LVTX | LAVA Therapeutics NV | 13 Feb 2025 | 1 | $0 | 4 | Chief Financial Officer | 18 Feb 2025, 20:15 |
| LVTX | LAVA Therapeutics NV | 01 Jan 2025 | 0 | $0 | 3 | Chief Financial Officer | 02 Jan 2025, 09:20 |
| ATRS | ANTARES PHARMA, INC. | 24 May 2022 | 9 | -$5,125,512 | 4 | Executive Vice President & CFO | 26 May 2022, 17:24 |
| ATRS | ANTARES PHARMA, INC. | 03 Mar 2022 | 2 | -$43,723 | 4 | Executive Vice President & CFO | 04 Mar 2022, 17:36 |
| ATRS | ANTARES PHARMA, INC. | 16 Feb 2022 | 2 | -$42,075 | 4 | Executive Vice President & CFO | 18 Feb 2022, 18:16 |
| ATRS | ANTARES PHARMA, INC. | 10 Jun 2021 | 4 | +$250,030 | 4 | Executive Vice President & CFO | 14 Jun 2021, 18:24 |
| ATRS | ANTARES PHARMA, INC. | 08 Jun 2021 | 1 | -$52,878 | 4 | Executive Vice President & CFO | 10 Jun 2021, 17:39 |